Proof-point cadence: the last promised marker just landed, and the next one is already on the clock
The model's full reasoning — Q3 2022 call → NOWe need to determine if management presents a live, checkable sequence of proof points with both a marker just delivered and a next marker named and near. Let's analyze the transcript. Management discusses various achievements: record revenue, active surgeon base growth, iFuse-TORQ record revenue, iFuse Bedrock Granite launch, FDA clearances, SAFFRON study enrollment, etc. But we need to see if they present a specific operational checkpoint just completed and a next one with timing. Key points: They mention "In September, we also received FDA clearance for iFuse-TORQ to include fusion in conjunction with spinal pelvic fixation." That's a concrete step. Also "In September, we enrolled the first of the targeted 120 patients on a SAFFRON study." That's a milestone. But are these presented as part of a sequence with a next step? They also talk about Granite supply chain issues and hospital approvals. They say "we continue to successfully work with major hospitals across the U.S. to get the product on the approved list." That's ongoing, not a specific next marker. They mention "we expect to see that as a tailwind in 2023" for reimbursement. But that's not a specific operational step. The question asks: Does management present a live, checkable sequence of proof points? They have multiple achievements, but do they explicitly say "we just did X, and next we will do Y by Z time"? They mention "we anticipate results to be available in late 2024" for SAFFRON, but that's far. They mention "we expect cash outflow to be in the same range as of third quarter" for Q4, but that's financial. They talk about Granite: "we are expecting a more moderated impact of it in the entire fourth quarter" and "we want to make sure that we see that work its way through the process and then feel like going into 2023, we are positioned well." That's vague. They also mention "we continue to see that acceleration continue partly from our core business, but also from our adult deformity business and from our trauma business" but no specific next checkpoint. The essence is a sequence: last checkpoint just cleared, next checkpoint on the clock. For example, they cleared FDA clearance for TORQ in September, and then they might say "next we will launch in trauma market by Q1 2023" but they don't.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CMPS | COMPASS Pathways plc | Q3 2023 | 2023-11-04 | F |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| HIW | Highwoods Properties, Inc. | Q4 2022 | 2023-02-08 | B |
| TCBI | Texas Capital Bancshares, Inc. | Q2 2021 | 2021-07-21 | F |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| XOM | Exxon Mobil Corporation | Q2 2018 | 2018-07-27 | C |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| CLMT | Calumet Specialty Products Partners, L.P | Q1 2018 | 2018-05-16 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| SCVL | Shoe Carnival, Inc. | Q4 2017 | 2018-03-27 | C+ |
| UPLD | Upland Software, Inc. | Q4 2017 | 2018-03-08 | C+ |
| ITCI | Intra-Cellular Therapies, Inc. | Q4 2017 | 2018-03-01 | D |
| INSM | Insmed Incorporated | Q4 2017 | 2018-02-23 | B |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| SBSI | Southside Bancshares, Inc. | Q4 2017 | 2018-02-06 | A |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| BP | BP p.l.c. | Q4 2016 | 2017-02-07 | B+ |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
XOM · Q2 2018 → YESThe question is whether management presents the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS with both a marker just delivered and the next marker named and near. YES Management presents a live, checkable sequence of proof points. In Neil Chapman's remarks, he explicitly notes that the Coral Floating LNG project is "progressing on schedule" and that "fabrication of the hull is expected to start in the third quarter of this year" — a concrete, near-term operational checkpoint 3–4 months away. Immediately prior, he states that "earlier this month, we announced that the development plan for the first phase has been submitted," treating that submission as the just-completed marker on the same path. He anchors the next step as "targeting final investment decision in 2019" with 2024 first LNG, presented as scheduled and already in motion rather than aspirational. This forms one coherent posture: the company is executing a verifiable execution sequence on the Mozambique LNG opportunity, with the development-plan submission just cleared and FID locked for 2019. Other examples (Baytown ethane cracker operations begun yesterday; 50 new Permian wells brought to sales in the quarter) exist, but the Mozambique LNG thread satisfies both required elements on a single forward path. No other elements (financial beats, routine maintenance, or analyst questions) are used to construct the sequence.
MKC · Q2 2018 → YESThe question is whether management presents the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS with both a marker just delivered and the next marker named and near. YES The transcript shows management framing the Frank's and French's integration as a completed checkpoint ("With the acquisition and integration complete"), then immediately naming and anchoring the next concrete steps on the same path — such as launching the first dedicated mustard campaign in the U.S. (kicked off this week during the call) and 2018 U.S. national TV advertising for Frank's in the second half — as scheduled, in-motion activities that will drive further growth. This is presented as one coherent execution sequence rather than isolated results. Other elements like distribution gains and summer grilling promotions are tied directly to this progression. No routine or vague items qualify; 2018 advertising and marketing acceleration are explicitly tied to the post-integration trajectory.
CMPS · Q3 2023 → YESThe question is whether management presents the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS with both a marker just delivered and the next marker named and near. YES The transcript shows management framing progress as a live execution sequence: the open-label PTSD Phase II study has just reached full recruitment (a concrete checkpoint passed), and they explicitly name the next marker — top-line readout this year — as the immediate follow-on step already in motion and scheduled within the coming months. This is presented as part of the same forward trajectory they are tracking, alongside the TRD Phase III where site initiations (3/4 of COMP005) are described as continuing to advance toward the summer 2024 readout.